Repurposing phosphodiesterase-5 inhibitors as chemoadjuvants

Frontiers in Pharmacology

Volumn 4 JUN, Issue , 2013, Pages

  Tiwari, Amit K ^a   Chen, Zhe Sheng ^b  

^a TUSKEGEE UNIVERSITY   (United States)

^b ST JOHN'S UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; CAPECITABINE; CYTOTOXIC AGENT; DOCETAXEL; DOXORUBICIN; PACLITAXEL; PHOSPHODIESTERASE V; PHOSPHODIESTERASE V INHIBITOR; PROSTATE SPECIFIC ANTIGEN; SILDENAFIL; SULINDAC; TADALAFIL; VARDENAFIL; VINBLASTINE;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BRAIN TUMOR; BREAST CANCER; CANCER INHIBITION; CEREBROVASCULAR ACCIDENT; DRUG CYTOTOXICITY; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME SUBSTRATE; ERECTILE DYSFUNCTION; HEART FAILURE; HUMAN; INCONTINENCE; LUNG NON SMALL CELL CANCER; NONHUMAN; NOTE; OVERACTIVE BLADDER; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROTEIN EXPRESSION; PULMONARY HYPERTENSION; RAYNAUD PHENOMENON; SEXUAL AROUSAL DISORDER; TREATMENT RESPONSE; TUMOR IMMUNITY;

EID: 84881646555     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2013.00082     Document Type: Note

References (24)

1. Bender, A. T., and Beavo, J. A. (2006). Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol. Rev. 58, 488-520. doi: 10.1124/pr.58.3.5
2. Black, K. L., Yin, D., Ong, J. M., Hu, J., Konda, B. M., Wang, X., et al. (2008). PDE5 inhibitors enhance tumor permeability and efficacy of chemotherapy in a rat brain tumor model. Brain Res. 1230, 290-302. doi: 10.1016/j.brainres.2008.06.122
3. Chavez, A. H., Scott Coffield, K., Hasan Rajab, M., and Jo, C. (2013). Incidence rate of prostate cancer in men treated for erectile dysfunction with phosphodiesterase type 5 inhibitors: retrospective analysis. Asian J. Androl. 15, 246-248. doi: 10.1038/aja.2012.162
4. Chen, J. J., Sun, Y. L., Tiwari, A. K., Xiao, Z. J., Sodani, K., Yang, D. H., et al. (2012). PDE5 inhibitors, sildenafil and vardenafil, reverse multidrug resistance by inhibiting the efflux function of multidrug resistance protein 7 (ATP-binding Cassette C10) transporter. Cancer Sci. 103, 1531-1537. doi: 10.1111/j.1349-7006.2012.02328.x
5. Chen, Z. S., Lee, K., and Kruh, G. D. (2001). Transport of cyclic nucleotides and estradiol 17-beta-D-glucuronide by multidrug resistance protein 4. Resistance to 6-mercaptopurine and 6-thioguanine. J. Biol. Chem. 276, 33747-33754. doi: 10.1074/jbc.M104833200
6. Das, A., Durrant, D., Mitchell, C., Mayton, E., Hoke, N. N., Salloum, F. N., et al. (2010). Sildenafil increases chemotherapeutic efficacy of doxorubicin in prostate cancer and ameliorates cardiac dysfunction. Proc. Natl. Acad. Sci. U.S.A. 107, 18202-18207. doi: 10.1073/pnas.1006965107
7. Das, A., Xi, L., and Kukreja, R. C. (2008). Protein kinase G-dependent cardioprotective mechanism of phosphodiesterase-5 inhibition involves phosphorylation of ERK and GSK3beta. J. Biol. Chem. 283, 29572-29585. doi: 10.1074/jbc.M801547200
8. Di, X., Gennings, C., Bear, H. D., Graham, L. J., Sheth, C. M., White, K. L., et al. (2010). Influence of the phosphodiesterase-5 inhibitor, sildenafil, on sensitivity to chemotherapy in breast tumor cells. Breast Cancer Res. Treat. 124, 349-360. doi: 10.1007/s10549-010-0765-7
9. Ding, P. R., Tiwari, A. K., Ohnuma, S., Lee, J. W., An, X., Dai, C. L., et al. (2011). The phosphodiesterase-5 inhibitor vardenafil is a potent inhibitor of ABCB1/P-glycoprotein transporter. PLoS ONE 6:e19329. doi: 10.1371/journal.pone.0019329
10. Hou, Y., Gupta, N., Schoenlein, P., Wong, E., Martindale, R., Ganapathy, V., et al. (2006). An anti-tumor role for cGMP-dependent protein kinase. Cancer Lett. 240, 60-68. doi: 10.1016/j.canlet.2005.08.035
11. Jedlitschky, G., Burchell, B., and Keppler, D. (2000). The multidrug resistance protein 5 functions as an ATP-dependent export pump for cyclic nucleotides. J. Biol. Chem. 275, 30069-30074. doi: 10.1074/jbc.M005463200
12. Li, H., Liu, L., David, M. L., Whitehead, C. M., Chen, M., Fetter, J. R., et al. (2002). Pro-apoptotic actions of exisulind and CP461 in SW480 colon tumor cells involve beta-catenin and cyclin D1 down-regulation. Biochem. Pharmacol. 64, 1325-1336. doi: 10.1016/S0006-2952(02)01345-X
13. Piazza, G. A., Thompson, W. J., Pamukcu, R., Alila, H. W., Whitehead, C. M., Liu, L., et al. (2001). Exisulind, a novel proapoptotic drug, inhibits rat urinary bladder tumorigenesis. Cancer Res. 61, 3961-3968.
14. Pusztai, L., Zhen, J. H., Arun, B., Rivera, E., Whitehead, C., Thompson, W. J., et al. (2003). Phase I and II study of exisulind in combination with capecitabine in patients with metastatic breast cancer. J. Clin. Oncol. 21, 3454-3461. doi: 10.1200/JCO.2003.02.114
15. Sandner, P., Hutter, J., Tinel, H., Ziegelbauer, K., and Bischoff, E. (2007). PDE5 inhibitors beyond erectile dysfunction. Int. J. Impot. Res. 19, 533-543. doi: 10.1038/sj.ijir.3901577
16. Sarfati, M., Mateo, V., Baudet, S., Rubio, M., Fernandez, C., Davi, F., et al. (2003). Sildenafil and vardenafil, types 5 and 6 phosphodiesterase inhibitors, induce caspase-dependent apoptosis of B-chronic lymphocytic leukemia cells. Blood 101, 265-269. doi: 10.1182/blood-2002-01-0075
17. Serafini, P., Meckel, K., Kelso, M., Noonan, K., Califano, J., Koch, W., et al. (2006). Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. J. Exp. Med. 203, 2691-2702. doi: 10.1084/jem.20061104
18. Shi, Z., Tiwari, A. K., Shukla, S., Robey, R. W., Singh, S., Kim, I. W., et al. (2011). Sildenafil reverses ABCB1- and ABCG2-mediated chemotherapeutic drug resistance. Cancer Res. 71, 3029-3041. doi: 10.1158/0008-5472.CAN-10-3820
19. Spoto, G., Fioroni, M., Rubini, C., Contento, A., Di Nicola, M., Forcella, S., et al. (2003). Cyclic guanosine monophosphate phosphodiesterase activity in human gingival carcinoma. J. Oral Pathol. Med. 32, 189-194. doi: 10.1034/j.1600-0714.2003.00083.x
20. Thompson, W. J., Piazza, G. A., Li, H., Liu, L., Fetter, J., Zhu, B., et al. (2000). Exisulind induction of apoptosis involves guanosine 3', 5'-cyclic monophosphate phosphodiesterase inhibition, protein kinase G activation, and attenuated beta-catenin. Cancer Res. 60, 3338-3342.
21. Tinsley, H. N., Gary, B. D., Keeton, A. B., Lu, W., Li, Y., and Piazza, G. A. (2011). Inhibition of PDE5 by sulindac sulfide selectively induces apoptosis and attenuates oncogenic Wnt/beta-catenin-mediated transcription in human breast tumor cells. Cancer Prev. Res. (Phila.) 4, 1275-1284. doi: 10.1158/1940-6207.CAPR-11-0095
22. Tiwari, A. K., Zhang, R., and Gallo, J. M. (2013). Overlapping functions of ABC transporters in topotecan disposition as determined in gene knockout mouse models. Mol. Cancer Ther. doi: 10.1158/1535-7163.MCT-13-0100. [Epub ahead of print].
23. 'Whitehead, C. M., Earle, K. A., Fetter, J., Xu, S., Hartman, T., Chan, D. C., et al. (2003). Exisulind-induced apoptosis in a non-small cell lung cancer orthotopic lung tumor model augments docetaxel treatment and contributes to increased survival. Mol. Cancer Ther. 2, 479-488.
24. Zhu, B., and Strada, S. J. (2007). The novel functions of cGMP-specific phosphodiesterase 5 and its inhibitors in carcinoma cells and pulmonary/cardiovascular vessels. Curr. Top. Med. Chem. 7, 437-454. doi: 10.2174/156802607779941198